Glatiramer Acetate [Design Issues]

posted by cakhatri – India, 2014-03-02 15:25 (4503 d 03:51 ago) – Posting: # 12544
Views: 7,129

Dear Members,
We have a requirement on conduct of study on Glatiramer acetate injection (20mg) for USFDA submission. The study is to be conducted in India. There are no FDA guidelines on conduct of the study for ANDA submission.Can anyone share their experience in conducting study with this molecule
Regards
Chirag

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
337 visitors (0 registered, 337 guests [including 18 identified bots]).
Forum time: 20:16 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5